Merkur Market listed Gentian Diagnostics AS has completed a private placement in two tranches raising NOK 100 million
Tranche 1 was directed to investors in general, subject to applicable selling restrictions from relevant prospectus requirements. Tranche 2 was directed to existing shareholders in the company holding less than 70,000 shares (as registered in the VPS as of 19 January 2017) and employees of the company who were not allocated shares in tranche 1. The indicative allocation of the gross proceed between Tranche 1 and 2 was 95 % - 5 %. Application period under tranche 1 was closed the same afternoon as the Private Placement was launched, on 19 January 2017, while the application period under tranche 2 was closed on 27 January 2017. Both tranches were over-subscribed.
The net proceeds from the Private Placement will be used to further develop the Gentian’s distribution platform, pursue selected identified M&A opportunities, as well as for general corporate purposes.
Aabø-Evensen & Co AS has acted as legal advisor to Gentian in connection with the transaction.
Click here to be redirected to the Stock Exchange Notice published 27 January 2017.